ClinicalTrials.Veeva

Menu
The trial is taking place at:
D

Dolphin Medical Research | Doral, FL

Veeva-enabled site

PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

A

ARJ Medical

Status and phase

Enrolling
Phase 3

Conditions

Helicobacter Pylori
Efficacy
Safety

Treatments

Diagnostic Test: Stool Antigen Test
Combination Product: PyloPlus Urea Breath Test System

Study type

Interventional

Funder types

Industry

Identifiers

NCT05276557
ARJ-2022-PED

Details and patient eligibility

About

This is a multi-center, non-randomized, open label study. Subjects will be enrolled on a walk-in basis. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All children will be exposed to non-radioactive 13C-Urea with citric acid, and shall submit a stool sample.

Centers will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyzer results shall remain blinded to the investigator and treating physician. No patient management decisions should be made based on the investigational PyloPlus® UBT System.

Treating physician will prescribe a H. Pylori Stool Antigen Test to Stool test at either LabCorp or Quest Diagnostic, for the patient, which will be used for diagnostic purposes by the ordering physician.

Total duration of study is anticipated to be approximately 6 months.

Enrollment

40 estimated patients

Sex

All

Ages

3 to 17 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male or female age 3-17 at the time of visit
  • Subject/Legal guardian (and subject when relevant) is willing to sing the Informed Consent/Assent Form
  • Naive to H. pylori treatment in the past 4 weeks

Exclusion criteria

  • Pregnant and/or lactating women
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient of the quality of data
  • Participation in other interventional trials
  • Allergy to test substrates
  • Antibiotics taken within 4 weeks of the testing
  • Study subjects shall not consume the following items at least 1 hour prior to the PPUBT test: Mouthwash, Chewing Gum, Carbonated Beverages, Cigarette Smoke, Acetone (to simulate the effect of ketone production that may result from some diets), Alcohol, Food
  • Children 12 years and older - to be excluded after a written notification from the sponsor is received at the site that the limit of (approx.) 1/3 of the sample size was achieved for this group

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 1 patient group

Indication for H. pylori testing
Experimental group
Description:
Walk in basis: Symptomatic patients of H. pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test (a single dose of 13C urea at 75mg in powder form, to be dissolved in potable water as the kit indicates) in addition to stool antigen test comparison.
Treatment:
Combination Product: PyloPlus Urea Breath Test System
Diagnostic Test: Stool Antigen Test

Trial contacts and locations

3

Loading...

Central trial contact

Clinical Trial Manager

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems